Related Experiment Video

Updated: Oct 30, 2025

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K

New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis

Irina Larionova1,2, Elena Kazakova1, Tatiana Gerashchenko2

  • 1Laboratory of Translational Cellular and Molecular Biomedicine, National Research Tomsk State University, 634050 Tomsk, Russia.

Cancers
|July 2, 2021
PubMed

Insights

Tumor-associated macrophages (TAMs) drive tumor angiogenesis by secreting factors like VEGF, explaining resistance to current therapies. Targeting TAMs offers a promising strategy for more effective anti-angiogenic cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Angiogenesis is vital for tumor growth, making its inhibition a key cancer treatment strategy.
  • Current anti-angiogenic drugs targeting VEGF or receptor tyrosine kinases show limited efficacy due to patient resistance.
  • Tumor-associated macrophages (TAMs) are identified as crucial inducers of tumor angiogenesis.

Purpose of the Study:

  • To review secreted angiogenic factors produced by TAMs.
  • To explain the mechanisms behind resistance to current anti-angiogenic therapies.
  • To discuss prospects for targeting TAMs in cancer treatment.

Main Methods:

  • Literature review of studies on TAMs and angiogenesis.
  • Analysis of secreted regulators of angiogenesis produced by TAMs.
  • Discussion of genetic and posttranscriptional control mechanisms.

Main Results:

  • TAMs secrete multiple pro-angiogenic factors including VEGF, SEMA, S100A, chitinase-like proteins, osteopontin, and SPARC.
  • Factors like COX-2 and Tie2 influence TAM pro-angiogenic activity.
  • These TAM-derived factors contribute to resistance against current anti-angiogenic drugs.

Conclusions:

  • Understanding TAM-driven angiogenesis is crucial for overcoming treatment resistance.
  • Targeting TAMs and their secreted factors presents a novel therapeutic avenue.
  • Complex targeting strategies for TAM pro-angiogenic activity hold promise for improved cancer therapy.
Keywords:
OPNRTK inhibitorS100ASEMASPARCVEGFangiogenesisanti-angiogenic therapycancertumor-associated macrophage

More Related Videos

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.3K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K